- About ASF
- What is Autism?
- How Common is Autism?
- Early Signs of Autism
- Autism Diagnosis
- Following a Diagnosis
- Treatment Options
- Beware of Non-Evidence-Based Treatments
- Statement on Use of Medical Marijuana for People with Autism
- Autism and Vaccines
- Autism Science
- Quick Facts About Autism
- What We Fund
- Autism Sisters Project
- Baby Siblings Research Consortium
- Resources for Grantees
- Funding Calendar
- ASF Funded Research
- ASF Supported Findings
- Apply for a Fellowship
- Apply for a Research Accelerator Grant
- Apply for an Undergraduate Summer Research Grant
- Get Involved
- Day of Learning
- Year End Summaries
- Contact Us
Research by Topic: Psychopharmacology
An estimated 32-92% of parents use complementary/alternative treatments for their children with ASD despite the lack of scientific evidence for the efficacy of these methods. In this article, researchers issue a call for a standardized way to select and evaluate treatments. Barriers to successful treatment, including high costs, limited availability, parental compliance and poor recommendations from professionals are discussed.
New Supplement in Pediatrics: Improving Health Care for Children and Youth With Autism and Other Neurodevelopmental DisordersPublished November 1, 2012 in Pediatrics
Access full articles on interventions, sleep and GI problems, health care coverage and more.
Roche and Seaside Therapeutics have entered an alliance to develop pharmacological treatments for autism spectrum disorders and Fragile X Syndrome.
A specific antioxidant supplement containing N-Acetylcysteine, or NAC may be an effective therapy for some features of autism, according to a pilot trial from the Stanford University School of Medicine and Lucile Packard Children’s Hospital that involved 31 children with the disorder.
Biological pathways revealed by the deeper list of ASD genes should narrow the targets for therapeutic intervention.
Researchers are conducting advanced trials of the first drugs expressly designed to correct the genetically induced signaling problems in the brain that result in autism. The early indications are positive enough to offer new hope for families and spark interest from drug companies.
In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
Doctors’ belief that certain antidepressants can help to treat repetitive behaviors in kids with autism may be based on incomplete information, according to a new review of published and unpublished research.
Experimental new drugs, AFQ056 (an mGluR5 antagonist from Novartis) and STX209 (arbaclofen from Seaside Therapeutics) are in large scale trials.
New Research Might Help Explain How a Gene Mutation Found in some Autistic Individuals Leads to Difficulties in Processing Auditory Cues and Paying Spatial Attention to Sound.Published February 2, 2012 in Science Daily
New research from Cold Spring Harbor Laboratory (CSHL) might help explain how a gene mutation found in some autistic individuals leads to difficulties in processing auditory cues and paying spatial attention to sound.
A new Vanderbilt study shows that the over-the-counter supplement melatonin is promising in helping children with autism spectrum disorders (ASD), and their families, sleep better.
As a psychiatrist and the parent of an adult son with autism, I found In Treating Disabled, Potent Drugs and Few Rules (front page, Dec. 23) to be unfair and detrimental to the families of the developmentally disabled. Although any medication can be inappropriately administered, the wholesale denigration of psychotropic medication for this population is misplaced.
About half of newborns who have seizures go on to have long-term intellectual and memory deficits and cognitive disorders such as autism, but why this occurs has been unknown. In the December 14 Journal of Neuroscience, researchers at Children’s Hospital Boston detail how early-life seizures disrupt normal brain development, and show in a rat model that it might be possible to reverse this pathology by giving certain drugs soon after the seizure.
Children exposed to the epilepsy drug valproate have a nearly three times higher risk of having an autism spectrum disorder, new research finds.
Repetitive behaviors in adults with Autism Spectrum disorders significantly lessen with antidepressant treatmentPublished December 5, 2011 in MedicalXpress
Restricted, repetitive behavior, such as compulsive arranging and rigid adherence to routines, is a defining symptom of autism spectrum disorders. A 12-week study showed that the antidepressant fluoxetine produced a greater decrease in repetitive behaviors and more overall improvement than placebo in adults with autism spectrum disorders.
The Institute for Basic Research in Staten Island is seeking adult participants for a new Fragile X treatment trial. This is a large scale trial of AFQ056 from Novartis for people aged 18-45 who have Fragile X. AFQ056 is an mGluR5 antagonist. The current study is just for adults but the next step is to extend the trial to ages 12-17. After completing the 20 week trial, participants will be offered the option of taking this medication free of charge until it comes to market.
A new strain of mice engineered to lack a gene with links to autism displays many of the hallmarks of the condition. It also responds to a drug in the same way as people with autism, which might open the way to new therapies for such people.
This study examined mouse neuronal cells during pregnancy to discover how the drug actually interferes at a molecular level with prostaglandins, which are important for development and communication of cells in the brain.
Researchers at the Center for Translational Social Neuroscience (CTSN) at Emory University are focusing on prairie voles as a new model to screen the effectiveness of drugs to treat autism. They are starting with D-cycloserine, a drug Emory researchers have shown enhances behavioral therapy for phobias and also promotes pair bonding among prairie voles. Giving female voles D-cycloserine, which is thought to facilitate learning and memory, can encourage them to bond with a new male more quickly than usual.
A new study found that treatment-resistant epilepsy (TRE) is common in idiopathic autism. Early age at the onset of seizures and delayed global development were associated with a higher frequency of resistance to antiepileptic drugs (AEDs). Full findings appear online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy (ILAE).
Treatments Show Promise in Reducing Autism-related Behaviors, but Some have Significant Side EffectsPublished April 4, 2011 in Agency for Heathcare Research and Quality
Some medical and behavioral treatments show promise for reducing certain behaviors in children with autism spectrum disorders (ASDs), but more research is needed to assess the potential benefits and harms, according to a new report funded by HHS’ Agency for Healthcare Research and Quality (AHRQ). The research results were published online in the journal Pediatrics.
Researchers at Vanderbilt University reviewed evidence regarding medical treatment of children 12 years old and younger with an Autism Spectrum Disorder (ASD). It was found that risperidone and aripiprazole for treatment of challenging and repetitive behaviors in children with ASDs. However, there are significant adverse effects of these medicines, including severe impairment or risk of […]
Krishnaswami et al. Researchers at Vanderbilt University found that secretin, a medical treatment for autism spectrum disorders (ASDs) that was popularized in the 1990s, is ineffective in the treatment of ASDs. Evidence from seven randomized controlled trials suggests that secretin does not effectively treat the symptoms of ASDs, which include language and communication impairment, symptom […]
The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise.
Eastern Virginia Medical School researchers have identified a potential novel treatment strategy for the social impairment of people with Autism Spectrum Disorders (ASD), an aspect of the condition that has a profound impact on quality of life.
The last two decades have seen tremendous progress in understanding the genetic basis of human brain disorders. Research developments in this area have revealed fundamental insights into the genes and molecular pathways that underlie neurological and psychiatric diseases. In a new series of review articles, experts in the field discuss exciting recent advances in neurogenetics research and the potential implications for the treatment of these devastating disorders.
A group of researchers at the University of Bristol have sequestered the potentially fatal breath holding episodes associated with the autistic-spectrum disorder Rett syndrome. Using a unique combination of drugs, they have discovered that the area of the brain that allows breathing to persist throughout life without interruption has reduced levels of a transmitter substance called aminobutyric acid.
Parents of children with fragile X syndrome report that minocycline led to positive improvements in language, attention levels and behavior. They also report experiencing adverse side effects such as mild gastrointestinal issues and some increased irritability.
The story of Matthew, a 9-year-old with Fragile X Syndrome, is one of the first patients on one of the first medications ever developed specifically to address the causes of an autism-like disorder. And at least for him it seems to be working.
Researchers at Emory University School of Medicine have identified a potential new strategy for treating fragile X syndrome — the most common inherited cause of intellectual disability. The researchers have found that a class of drugs called phosphoinositide-3 (PI3) kinase inhibitors can correct defects in the anatomy of neurons seen in a mouse model of fragile X syndrome.
Antidepressants commonly prescribed to people with autistic spectrum disorders cannot be recommended based on current evidence, a new study by Cochrane Researchers concludes. Despite some evidence of benefits in adults diagnosed with autism, they say there is no evidence for any benefits associated with selective serotonin reuptake inhibitors (SSRIs) in children, who may suffer serious adverse effects as a result of taking the drugs.
A product promoted to parents of children with autism is not a harmless dietary supplement, as claimed, but a toxic unapproved drug that lacks adequate warnings about potential side effects, including hair loss and abnormalities of the pancreas, the U.S. Food and Drug Administration has warned in a letter to its maker.
Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category.
Researchers identified a rare genetic mutation that may open a new avenue for treating Tourette syndrome in a study published Wednesday that examined a family in which the father and all eight children suffer from the neurological disorder.The family’s mutation affected a gene required to produce histamine. Pharmaceutical companies are already developing drugs for other conditions that target the brain’s histamine system. The study’s researchers are planning a clinical trial of adults with Tourette to see if those drugs would help control the motor and vocal tics that characterize the condition.
Moderators, Mediators,and Other Predictors of Risperidone Response in Children with Autistic Disorder and IrritabilityPublished April 1, 2010 in Journal of Childhood and Adolescent Psychopharmacology, Arnold et al
The National Institute of Mental Health (NIMH) Research Units on Pediatric Psychopharmacology (RUPP) Autism Network found an effect size of d = 1.2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder. This paper explores moderators and mediators of this effect. This study found […]
A genetic link between schizophrenia and autism is enabling researchers to study the effectiveness of drugs used to treat both illnesses. Dr. Steve Clapcote from the University of Leeds’s Faculty of Biological Sciences will be analyzing behavior displayed by mice with a genetic mutation linked to schizophrenia and autism and seeing how antipsychotic drugs affect their behavioral abnormalities.
When a gene implicated in human autism is disabled in mice, the rodents show learning problems and obsessive, repetitive behaviors, researchers at UT Southwestern Medical Center have found. The researchers also report that a drug affecting a specific type of nerve function reduced the obsessive behavior in the animals, suggesting a potential way to treat repetitive behaviors in humans
Autism is a disease characterized by difficulties in communicating effectively with other people and developing social relationships. A team led by Angela Sirigu at the Centre de Neuroscience Cognitive (CNRS) has shown that the inhalation of oxytocin, a hormone known to promote mother-infant bonds and social relationships, significantly improved the abilities of autistic patients to interact with other individuals.
An industrial chemical developed to help separate heavy metals from polluted soil and mining drainage is being sold as a dietary supplement by a luminary in the world of alternative autism treatments. Called OSR#1, the supplement is described on its Web site as an antioxidant not meant to treat any disease. But the site lists pharmacies and doctors who sell it to parents of children with autism, and the compound has been promoted to parents on popular autism Web sites. A search of medical journals unearthed no papers published about OSR#1, though the compound’s industrial uses have been explored in publications such as the Journal of Hazardous Materials.
Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive BehaviorPublished June 1, 2009 in Archives of General Psychiatry, King, Hollander, Sikich, McCracken, Scahill, Bregman, Donnelly, Anagnostou, Dukes, Sullivan, Hirtz, Wagner, Louise Ritz; for the STAART Psychopharmacology Network
Citalopram (Celexa), a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to a multi-site clinical trial guided by lead author Bryan King, MD, director of child and adolescent psychiatry at Seattle Children's Hospital and professor and vice chair of psychiatry at […]
Rett Syndrome (RTT) is a severe form of X-linked mental retardation caused by mutations in the gene coding for methyl CpG-binding protein 2 (MECP2). Mice deficient in MeCP2 have a range of physiological and neurological abnormalities that mimic the human syndrome. Here we show that systemic treatment of MeCP2 mutant mice with an active peptide […]
Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccinesPublished January 1, 2009 in Pediatrics, Tozzi AE, Bisiacchi P, Tarantino V, De Mei B, D'Elia L, Chariotti F, Salmaso S.
Thimerosal, a mercury compound used as a preservative in vaccines administered during infancy, has been suspected to affect neuropsychological development. We compared the neuropsychological performance, 10 years after vaccination, of 2 groups of children exposed randomly to different amounts of thimerosal through immunization. Children who were enrolled in an efficacy trial of pertussis vaccines in […]